These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 25945831)

  • 1. Determination of the rat in vivo pharmacokinetic profile of a bone-targeting dual-action pro-drug for treatment of osteoporosis.
    Chen G; Arns S; Young RN
    Bioconjug Chem; 2015 Jun; 26(6):1095-103. PubMed ID: 25945831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of novel bone-targeting dual-action pro-drugs for the treatment and reversal of osteoporosis.
    Arns S; Gibe R; Moreau A; Monzur Morshed M; Young RN
    Bioorg Med Chem; 2012 Mar; 20(6):2131-40. PubMed ID: 22341574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis, and Pharmacokinetics of a Bone-Targeting Dual-Action Prodrug for the Treatment of Osteoporosis.
    Xie H; Chen G; Young RN
    J Med Chem; 2017 Aug; 60(16):7012-7028. PubMed ID: 28699744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel EP4 receptor agonist-bisphosphonate conjugate drug (C1) promotes bone formation and improves vertebral mechanical properties in the ovariectomized rat model of postmenopausal bone loss.
    Liu CC; Hu S; Chen G; Georgiou J; Arns S; Kumar NS; Young RN; Grynpas MD
    J Bone Miner Res; 2015 Apr; 30(4):670-80. PubMed ID: 25284325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting therapeutics to bone by conjugation with bisphosphonates.
    Young RN; Grynpas MD
    Curr Opin Pharmacol; 2018 Jun; 40():87-94. PubMed ID: 29626715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A query from medical practice: the biological half-life of biphosphonates].
    Bartl R
    Dtsch Med Wochenschr; 2008 Dec; 133(51-52):2700-1. PubMed ID: 19067274
    [No Abstract]   [Full Text] [Related]  

  • 7. Bisphosphonate therapy and dental treatment.
    Phillips G
    J Indiana Dent Assoc; 2007-2008 Winter; 86(4):4-8. PubMed ID: 18363257
    [No Abstract]   [Full Text] [Related]  

  • 8. Prolonged bisphosphonate release after treatment in children.
    Papapoulos SE; Cremers SC
    N Engl J Med; 2007 Mar; 356(10):1075-6. PubMed ID: 17347467
    [No Abstract]   [Full Text] [Related]  

  • 9. Design, synthesis, and biological evaluation of novel estradiol-bisphosphonate conjugates as bone-specific estrogens.
    Morioka M; Kamizono A; Takikawa H; Mori A; Ueno H; Kadowaki S; Nakao Y; Kato K; Umezawa K
    Bioorg Med Chem; 2010 Feb; 18(3):1143-8. PubMed ID: 20071185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and study of alendronate derivatives as potential prodrugs of alendronate sodium for the treatment of low bone density and osteoporosis.
    Vachal P; Hale JJ; Lu Z; Streckfuss EC; Mills SG; MacCoss M; Yin DH; Algayer K; Manser K; Kesisoglou F; Ghosh S; Alani LL
    J Med Chem; 2006 Jun; 49(11):3060-3. PubMed ID: 16722624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates, phossy jaw, and bisphosphonate-related osteonecrosis of the jaw.
    Lewis DM
    J Okla Dent Assoc; 2011; 102(5):36-9. PubMed ID: 21874699
    [No Abstract]   [Full Text] [Related]  

  • 12. Prostaglandin EP4 receptor agonist augments fixation of hydroxyapatite-coated implants in a rat model of osteoporosis.
    Hayashi K; Fotovati A; Ali SA; Oda K; Oida H; Naito M
    J Bone Joint Surg Br; 2005 Aug; 87(8):1150-6. PubMed ID: 16049256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term use of bisphosphonates in osteoporosis.
    Watts NB; Diab DL
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1555-65. PubMed ID: 20173017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bisphosphonate treatment of osteoporosis and other skeletal diseases].
    Syversen U; Halse JI
    Tidsskr Nor Laegeforen; 2011 Feb; 131(3):244-7. PubMed ID: 21304573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New therapy using bisphosphonate for urolithiasis].
    Yasui T; Niimi K; Hirose M
    Clin Calcium; 2011 Oct; 21(10):1511-5. PubMed ID: 21960237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microgravity and drug effects on bone.
    Shapiro JR
    J Musculoskelet Neuronal Interact; 2006; 6(4):322-3. PubMed ID: 17185807
    [No Abstract]   [Full Text] [Related]  

  • 17. [Bisphosphonate therapy for osteoporosis and bone strength].
    Kishimoto H
    Clin Calcium; 2006 Sep; 16(9):1513-19. PubMed ID: 16951477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, Synthesis, Pharmacokinetics, and Biodistribution of a Series of Bone-Targeting EP4 Receptor Agonist Prodrugs for Treatment of Osteoporosis and Other Bone Conditions.
    Thévenin M; Chen G; Kantham S; Sun C; Glogauer M; Young RN
    ACS Pharmacol Transl Sci; 2021 Apr; 4(2):908-925. PubMed ID: 33860210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals.
    Lin JH; Duggan DE; Chen IW; Ellsworth RL
    Drug Metab Dispos; 1991; 19(5):926-32. PubMed ID: 1686238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biodistribution and plasma protein binding of zoledronic acid.
    Weiss HM; Pfaar U; Schweitzer A; Wiegand H; Skerjanec A; Schran H
    Drug Metab Dispos; 2008 Oct; 36(10):2043-9. PubMed ID: 18625688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.